USPTO Patent US12582667B2 for Gastrointestinal Cancer Treatment

The United States Patent and Trademark Office (USPTO) has issued patent US12582667B2, granting exclusive rights to The Rockefeller University for a novel treatment of metastatic gastrointestinal cancer. The patent specifically covers compositions and methods that suppress the enzymatic activity of DHODH and/or decrease creatine levels by inhibiting the creatine transporter SLC6a8. This patent is based on application number 17762529, filed on September 25, 2020, and has 32 claims.

This patent grant is primarily of interest to pharmaceutical and drug manufacturing companies involved in oncology research and development. While it does not impose direct compliance obligations on other entities, it represents a significant intellectual property development in the therapeutic area of gastrointestinal cancer. Companies operating in this space should be aware of this granted patent to ensure their own research and development activities do not infringe upon the patented claims.